Last reviewed · How we verify
SEVIKAR
At a glance
| Generic name | SEVIKAR |
|---|---|
| Also known as | amlodipine + olemsartan |
| Sponsor | Sang Hyun Ihm, MD PhD |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab (PHASE4)
- A Clinical Trial to Evaluate the Efficacy and Safety of Olmesartan/Amlodipine/Rosuvastatin Combination Treatment in Patients With Concomitant Hypertension and Hyperlipidemia (PHASE3)
- Clinical Trail to Evaluate the Efficacy and Safety of DWJ1451 (PHASE3)
- Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure (PHASE4)
- Clinical Trial to Investigate the Efficacy and Safety of DWJ1351 (PHASE1)
- Efficacy and Safety of a Therapy Change From Candesartan 32 mg to Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg (PHASE4)
- Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivikar Tab. 5/40 mg in Healthy Adult Male Subjects (PHASE1)
- Sevicontrol-1: Efficacy and Safety of a Fixed Combination of Olmesartan/ Amlodipine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SEVIKAR CI brief — competitive landscape report
- SEVIKAR updates RSS · CI watch RSS
- Sang Hyun Ihm, MD PhD portfolio CI